(MedPage Today) — CHICAGO — Novel orexin receptor 2 agonist oveporexton normalized wakefulness for most people with narcolepsy type 1 in two randomized phase III trials.
Mean sleep latency across four, 40-minute Maintenance of Wakefulness…
Source link : https://www.medpagetoday.com/meetingcoverage/chest/118089
Author :
Publish date : 2025-10-22 19:27:00
Copyright for syndicated content belongs to the linked Source.
